NASDAQ:ENLV

Enlivex Therapeutics Stock Forecast, Price & News

$5.50

-0.46 (-7.72%)

(As of 01/21/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.45
▼
$5.84
50-Day Range: $5.50
▼
$8.53
52-Week Range: $5.45
▼
$29.40

Volume: 126,758 shs
Average Volume: 78,261 shs
Market Capitalization: $100.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 1.13

30 days | 90 days | 365 days | Advanced Chart

Receive ENLV News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.

Enlivex to Detail the Application of its Innovative Macrophage Reprogramming Cell Therapy to Unmet Needs in Oncology at the 11th Annual LifeSci Partners Corporate Access Event
January 3, 2022 | finance.yahoo.com

Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
December 13, 2021 | finance.yahoo.com

Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
December 7, 2021 | finance.yahoo.com

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra
December 6, 2021 | finance.yahoo.com

Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 22, 2021 | finance.yahoo.com

Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
November 10, 2021 | finance.yahoo.com

Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain
November 4, 2021 | finance.yahoo.com

Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
October 27, 2021 | finance.yahoo.com

We're Not Very Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
October 12, 2021 | nasdaq.com

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
October 12, 2021 | ca.finance.yahoo.com

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
October 12, 2021 | finance.yahoo.com

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis
October 4, 2021 | finance.yahoo.com

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021
September 29, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ENLV
Previous Symbol
CUSIP: N/A
CIK: 1596812
Web: www.enlivex.com
Phone: (722) 670-8072
Fax: N/A
Employees: 50
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.64 per share
Price / Book: 2.08

Profitability

EPS (Most Recent Fiscal Year): ($0.98)
Net Income: $-11.82 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -20.50%
Return on Assets: -18.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.08
Quick Ratio: 19.08

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 18,311,000
Free Float: N/A
Market Cap: $100.71 million
Optionable: Not Optionable

Company Calendar

Last Earnings: 11/21/2021
Today: 1/22/2022
Next Earnings (Estimated): 4/29/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

962nd out of 1,418 stocks

Pharmaceutical Preparations Industry

472nd out of 684 stocks

3.5 Analyst's Opinion

Consensus Rating
Enlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.00, Enlivex Therapeutics has a forecasted upside of 500.0% from its current price of $5.50.
Amount of Analyst Coverage
Enlivex Therapeutics has received no research coverage in the past 90 days.

5.0 Community Rank

Outperform Votes
Enlivex Therapeutics has received 44 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Enlivex Therapeutics has received 11 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Enlivex Therapeutics has received 80.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Enlivex Therapeutics and other stocks. Vote “Outperform” if you believe ENLV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENLV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Enlivex Therapeutics does not currently pay a dividend.
Dividend Growth
Enlivex Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 4.63% of the stock of Enlivex Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enlivex Therapeutics is -5.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enlivex Therapeutics is -5.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enlivex Therapeutics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Enlivex Therapeutics (NASDAQ:ENLV) Frequently Asked Questions

Is Enlivex Therapeutics a buy right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enlivex Therapeutics stock.
View analyst ratings for Enlivex Therapeutics or view top-rated stocks.
How has Enlivex Therapeutics' stock been impacted by Coronavirus?: Enlivex Therapeutics' stock was trading at $5.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENLV stock has decreased by 4.7% and is now trading at $5.50.
View which stocks have been most impacted by COVID-19.
When is Enlivex Therapeutics' next earnings date?: Enlivex Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, April 29th 2022.
View our earnings forecast for Enlivex Therapeutics.
How were Enlivex Therapeutics' earnings last quarter?: Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced its earnings results on Sunday, November, 21st. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.02.
View Enlivex Therapeutics' earnings history.
What price target have analysts set for ENLV?: 1 Wall Street analysts have issued 1 year price objectives for Enlivex Therapeutics' shares. Their forecasts range from $33.00 to $33.00. On average, they expect Enlivex Therapeutics' share price to reach $33.00 in the next year. This suggests a possible upside of 500.0% from the stock's current price.
View analysts' price targets for Enlivex Therapeutics or view top-rated stocks among Wall Street analysts.
Who are Enlivex Therapeutics' key executives?: Enlivex Therapeutics' management team includes the following people:
Oren Hershkovitz, Chief Executive Officer
Shachar Shlosberger, Chief Financial Officer
Dror Mevorach, Chief Scientific & Medical Officer
Odelia Ben-Shitrit, Head-Clinical Operations
Who are some of Enlivex Therapeutics' key competitors?: Some companies that are related to Enlivex Therapeutics include Vera Therapeutics (VERA), Aadi Bioscience (AADI), Affimed (AFMD), Veru (VERU), Pliant Therapeutics (PLRX), Theseus Pharmaceuticals (THRX), Verona Pharma (VRNA), Adicet Bio (ACET), Marinus Pharmaceuticals (MRNS), Spero Therapeutics (SPRO), Allakos (ALLK), Dyne Therapeutics (DYN), G1 Therapeutics (GTHX), Generation Bio (GBIO) and Mersana Therapeutics (MRSN).
View all of ENLV's competitors.
What other stocks do shareholders of Enlivex Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).
What is Enlivex Therapeutics' stock symbol?: Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV."
Who are Enlivex Therapeutics' major shareholders?: Enlivex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Golden Green Inc. (0.11%).
Which institutional investors are selling Enlivex Therapeutics stock?: ENLV stock was sold by a variety of institutional investors in the last quarter, including Golden Green Inc..
How do I buy shares of Enlivex Therapeutics?: Shares of ENLV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enlivex Therapeutics' stock price today?: One share of ENLV stock can currently be purchased for approximately $5.50.
How much money does Enlivex Therapeutics make?: Enlivex Therapeutics has a market capitalization of $100.71 million. The company earns $-11.82 million in net income (profit) each year or ($0.98) on an earnings per share basis.
How many employees does Enlivex Therapeutics have?: Enlivex Therapeutics employs 50 workers across the globe.
What is Enlivex Therapeutics' official website?: The official website for Enlivex Therapeutics is www.enlivex.com.
Where are Enlivex Therapeutics' headquarters?: Enlivex Therapeutics is headquartered at 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042.
How can I contact Enlivex Therapeutics?: Enlivex Therapeutics' mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The company can be reached via phone at (722) 670-8072 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enlivex Therapeutics Stock Forecast, Price & News

About Enlivex Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

0.0 Company Ownership

0.0 Earnings and Valuation

Enlivex Therapeutics (NASDAQ:ENLV) Frequently Asked Questions

Is Enlivex Therapeutics a buy right now?

How has Enlivex Therapeutics' stock been impacted by Coronavirus?

When is Enlivex Therapeutics' next earnings date?

How were Enlivex Therapeutics' earnings last quarter?

What price target have analysts set for ENLV?

Who are Enlivex Therapeutics' key executives?

Who are some of Enlivex Therapeutics' key competitors?

What other stocks do shareholders of Enlivex Therapeutics own?

What is Enlivex Therapeutics' stock symbol?

Who are Enlivex Therapeutics' major shareholders?

Which institutional investors are selling Enlivex Therapeutics stock?

How do I buy shares of Enlivex Therapeutics?

What is Enlivex Therapeutics' stock price today?

How much money does Enlivex Therapeutics make?

How many employees does Enlivex Therapeutics have?

What is Enlivex Therapeutics' official website?

Where are Enlivex Therapeutics' headquarters?

How can I contact Enlivex Therapeutics?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™